Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.40 |
| ▸ | GGT1 | P19440 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17378062 | 1.00 | KDM4E (0.54) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL900182 | 1.00 | KDM4E (0.54) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Hydrochloric Acid SCHEMBL16993797 | 0.97 | KDM4E (0.52) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Ethylene SCHEMBL28132201 | 0.95 | KDM4E (0.50) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL7259702 | 0.90 | KDM4E (0.50) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL2774313 | 0.89 | KDM4E (0.50) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL17378053 | 0.89 | KDM4E (0.45) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL17377986 | 0.89 | KDM4E (0.55) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL2774315 | 0.89 | KDM4E (0.50) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL20259387 | 0.89 | KDM4E (0.45) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 644 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986465-B1 | SITE-SPECIFIC, KINETICALLY INERT CONJUGATION OF LABELS AND/OR CARRIERS TO TARGET MOLECULES SUCH AS HIS-TAGGED PROTEINS VIA METAL COMPLEX REAGENTS | MAX PLANCK GESELLSCHAFT (DE) | 2026-05-13 | — | — | EP | claimed |
| EP-4713029-A1 | MODIFIED CELL, PHARMACEUTICAL COMPOSITION AND METHOD OF PREPARING A MODIFIED CELL | Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V. (DE) | 2026-03-25 | — | — | EP | claimed |
| US-20260048156-A1 | FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS | Atoms for Cure GmbH (DE) | 2026-02-19 | — | — | US | claimed |
| US-20250235566-A1 | TRISLINKER-CONJUGATED DIMERIC LABELING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | Medianezia GmbH (DE) | 2025-07-24 | — | — | US | claimed |
| EP-4486395-A1 | PRECURSOR MARKERS AND RADIOTRACERS WITH THREE OR MORE TARGETING VECTORS FOR THERANOSTICS USED IN NUCLEAR MEDICINE | Atoms for Cure GmbH (DE) | 2025-01-08 | — | — | EP | claimed |
| WO-2024261219-A1 | MODIFIED CELL, PHARMACEUTICAL COMPOSITION AND METHOD OF PREPARING A MODIFIED CELL | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-12-26 | — | — | WO | claimed |
| EP-4480500-A1 | MODIFIED CELL, PHARMACEUTICAL COMPOSITION AND METHOD OF PREPARING A MODIFIED CELL | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-12-25 | — | — | EP | claimed |
| EP-4452326-A1 | FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS | Atoms for Cure GmbH (DE) | 2024-10-30 | — | — | EP | claimed |
| CN-118541171-A | FAP-targeted pharmaceutical products for cancer treatment and diagnosis | 原子治疗有限公司 | 2024-08-23 | — | — | CN | claimed |
| EP-4351663-A1 | TRISLINKER-CONJUGATED DIMERIC LABELLING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | Medianezia GmbH (DE) | 2024-04-17 | — | — | EP | claimed |
| WO-2003072143-A1 | COMPOSITIONS FOR DELIVERY OF THERAPEUTICS AND OTHER MATERIALS, AND METHODS OF MAKING AND USING THE SAME | PHARMAIN, LTD. (US) | 2003-09-04 | — | — | WO | claimed |
| EP-1326523-A2 | IMAGING OF ENZYMATIC ACTIVITY | THE GENERAL HOSPITAL CORPORATION (US) | 2003-07-16 | — | — | EP | claimed |
| EP-0711178-B1 | BLOOD POOL IMAGING COMPOSITION AND METHOD OF ITS USE | GEN HOSPITAL CORP (US) | 2003-05-21 | — | — | EP | claimed |
| WO-2002032291-A9 | IMAGING OF ENZYMATIC ACTIVITY | GEN HOSPITAL CORP (US) | 2003-04-17 | — | — | WO | claimed |
| EP-1286704-A2 | ETHYLENEDICYSTEINE (EC)-DRUG CONJUGATES | Board of Regents, The University of Texas System (US) | 2003-03-05 | — | — | EP | claimed |
| US-20020127629-A1 | Imaging of enzymatic activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-12 | — | — | US | claimed |
| WO-2002032291-A2 | IMAGING OF ENZYMATIC ACTIVITY | THE GENERAL HOSPITAL CORPORATION (US) | 2002-04-25 | — | — | WO | claimed |
| WO-2001091807-A2 | ETHYLENEDICYSTEINE (EC)-DRUG CONJUGATES | BOARD OF REGENTS (US) | 2001-12-06 | — | — | WO | claimed |
| US-6284220-B1 | Noninvasive imaging of nucleic acid vectors | THE GENERAL HOSPITAL CORPORATION | 2001-09-04 | — | — | US | claimed |
| US-5605672-A | Blood pool imaging composition and method of its use | THE GENERAL HOSPITAL CORPORATION (US) | 1997-02-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048156-A1 | FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS | FAP, ALK, FIBP | KDM4E 2871/4885MAPT 3883/4885THRB 427/4885 |
| US-20020127629-A1 | Imaging of enzymatic activity | MMP1, ENGASE, MMP2 | KDM4E 919/4885MAPT 2637/4885THRB 3950/4885 |
| US-20250235566-A1 | TRISLINKER-CONJUGATED DIMERIC LABELING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | TK1, TK2, TMT1A | KDM4E 4412/4885MAPT 2314/4885THRB 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.